Chapter 15 : Use of Traditional and Genetically Modified Probiotics in Human Health: What Does the Future Hold?

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:
Zoom in

Use of Traditional and Genetically Modified Probiotics in Human Health: What Does the Future Hold?, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555819705/9781555819699_Chap15-1.gif /docserver/preview/fulltext/10.1128/9781555819705/9781555819699_Chap15-2.gif


Advances in recombinant technology (e.g., genetic engineering) and in the understanding of the human immune system have led to prodigious advances in the development of novel delivery systems for mucosal administration ( ). The administration of therapeutic molecules through mucosal routes offers several important advantages over conventional strategies (i.e., systemic injection) such as reduction of secondary effects, easy administration, and the possibility to modulate both systemic and mucosal immune responses ( ). Moreover, it is important for molecules of health interest that exert their effects at mucosal surfaces, the gastrointestinal tract (GIT), for example, to be delivered directly to the appropriate site. Nonetheless, a major disadvantage of the mucosal route of administration is that the actual amount of protein to be administered needs to be large due to the very small quantities of protein that survive degradation at mucosal surfaces such as the GIT ( ).

Citation: Bermúdez-Humarán L, Langella P. 2018. Use of Traditional and Genetically Modified Probiotics in Human Health: What Does the Future Hold?, p 363-370. In Britton R, Cani P (ed), Bugs as Drugs. ASM Press, Washington, DC. doi: 10.1128/microbiolspec.BAD-0016-2016
Highlighted Text: Show | Hide
Loading full text...

Full text loading...


1. Bermúdez-Humarán LG,, Aubry C,, Motta JP,, Deraison C,, Steidler L,, Vergnolle N,, Chatel JM,, Langella P . 2013. Engineering lactococci and lactobacilli for human health. Curr Opin Microbiol 16 : 278 283.[CrossRef] [PubMed]
2. Davitt CJ,, Lavelle EC . 2015. Delivery strategies to enhance oral vaccination against enteric infections. Adv Drug Deliv Rev 91 : 52 69.[CrossRef] [PubMed]
3. Holmgren J,, Czerkinsky C . 2005. Mucosal immunity and vaccines. Nat Med 11( Suppl) : S45 S53.[CrossRef] [PubMed]
4. Bermúdez-Humarán LG,, Kharrat P,, Chatel JM,, Langella P . 2011. Lactococci and lactobacilli as mucosal delivery vectors for therapeutic proteins and DNA vaccines. Microb Cell Fact 10( Suppl 1) : S4.[CrossRef] [PubMed]
5. Food and Agriculture Organization of the United Nations . 2002. Joint FAO/WHO Working Group report on drafting guidelines for the evaluation of probiotics in food. Food and Agriculture Organization, London, Canada.
6. Lilly DM,, Stillwell RH . 1965. Probiotics: growth-promoting factors produced by microorganisms. Science 147 : 747 748.[CrossRef] [PubMed]
7. Martín R,, Miquel S,, Ulmer J,, Kechaou N,, Langella P,, Bermúdez-Humarán LG . 2013. Role of commensal and probiotic bacteria in human health: a focus on inflammatory bowel disease. Microb Cell Fact 12 : 71.[CrossRef] [PubMed]
8. Hill C,, Guarner F,, Reid G,, Gibson GR,, Merenstein DJ,, Pot B,, Morelli L,, Canani RB,, Flint HJ,, Salminen S,, Calder PC,, Sanders ME . 2014. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 11 : 506 514.[CrossRef] [PubMed]
9. Hempel S,, Newberry SJ,, Maher AR,, Wang Z,, Miles JNV,, Shanman R,, Johnsen B,, Shekelle PG . 2012. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA 307 : 1959 1969.[CrossRef] [PubMed]
10. Jijon H,, Backer J,, Diaz H,, Yeung H,, Thiel D,, McKaigney C,, De Simone C,, Madsen K . 2004. DNA from probiotic bacteria modulates murine and human epithelial and immune function. Gastroenterology 126 : 1358 1373.[CrossRef] [PubMed]
11. Gionchetti P,, Rizzello F,, Venturi A,, Brigidi P,, Matteuzzi D,, Bazzocchi G,, Poggioli G,, Miglioli M,, Campieri M . 2000. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 119 : 305 309.[CrossRef] [PubMed]
12. Kruis W,, Fric P,, Pokrotnieks J,, Lukás M,, Fixa B,, Kascák M,, Kamm MA,, Weismueller J,, Beglinger C,, Stolte M,, Wolff C,, Schulze J . 2004. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 53 : 1617 1623.[CrossRef] [PubMed]
13. O’Mahony L,, McCarthy J,, Kelly P,, Hurley G,, Luo F,, Chen K,, O’Sullivan GC,, Kiely B,, Collins JK,, Shanahan F,, Quigley EMM . 2005. Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 128 : 541 551.[CrossRef] [PubMed]
14. Schultz M,, Veltkamp C,, Dieleman LA,, Grenther WB,, Wyrick PB,, Tonkonogy SL,, Sartor RB . 2002. Lactobacillus plantarum 299V in the treatment and prevention of spontaneous colitis in interleukin-10-deficient mice. Inflamm Bowel Dis 8 : 71 80.[CrossRef] [PubMed]
15. Lenoir M,, Del Carmen S,, Cortes-Perez NG,, Lozano-Ojalvo D,, Munoz-Provencio D,, Chain F,, Langella P,, de Moreno de LeBlanc A,, LeBlanc JG,, Bermudez-Humaran LG . 2016. Lactobacillus casei BL23 regulates Treg and Th17 T-cell populations and reduces DMH-associated colorectal cancer. J Gastroenterol 51 : 862 873.[PubMed]
16. Rochet V,, Rigottier-Gois L,, Ledaire A,, Andrieux C,, Sutren M,, Rabot S,, Mogenet A,, Bresson JL,, Cools S,, Picard C,, Goupil-Feuillerat N,, Doré J . 2008. Survival of Bifidobacterium animalis DN-173 010 in the faecal microbiota after administration in lyophilised form or in fermented product: a randomised study in healthy adults. J Mol Microbiol Biotechnol 14 : 128 136.[CrossRef] [PubMed]
17. Martín R,, Laval L,, Chain F,, Miquel S,, Natividad J,, Cherbuy C,, Sokol H,, Verdu EF,, van Hylckama Vlieg J,, Bermudez-Humaran LG,, Smokvina T,, Langella P . 2016. Bifidobacterium animalis ssp. lactis CNCM-I2494 restores gut barrier permeability in chronically low-grade inflamed mice. Front Microbiol 7 : 608.[CrossRef] [PubMed]
18. Isolauri E,, Joensuu J,, Suomalainen H,, Luomala M,, Vesikari T . 1995. Improved immunogenicity of oral D x RRV reassortant rotavirus vaccine by Lactobacillus casei GG. Vaccine 13 : 310 312.[CrossRef]
19. Bhattacharyya A,, Chattopadhyay R,, Mitra S,, Crowe SE . 2014. Oxidative stress: an essential factor in the pathogenesis of gastrointestinal mucosal diseases. Physiol Rev 94 : 329 354.[CrossRef] [PubMed]
20. Rochat T,, Bermúdez-Humarán L,, Gratadoux JJ,, Fourage C,, Hoebler C,, Corthier G,, Langella P . 2007. Anti-inflammatory effects of Lactobacillus casei BL23 producing or not a manganese-dependant catalase on DSS-induced colitis in mice. Microb Cell Fact 6 : 22.[CrossRef] [PubMed]
21. Santos Rocha C,, Lakhdari O,, Blottière HM,, Blugeon S,, Sokol H,, Bermúdez-Humarán LG,, Azevedo V,, Miyoshi A,, Doré J,, Langella P,, Maguin E,, van de Guchte M . 2012. Anti-inflammatory properties of dairy lactobacilli. Inflamm Bowel Dis 18 : 657 666.[CrossRef] [PubMed]
22. Torres-Maravilla E,, Lenoir M,, Mayorga-Reyes L,, Allain T,, Sokol H,, Langella P,, Sánchez-Pardo ME,, Bermúdez-Humarán LG . 2016. Identification of novel anti-inflammatory probiotic strains isolated from pulque. Appl Microbiol Biotechnol 100 : 385 396.[CrossRef] [PubMed]
23. Grompone G,, Martorell P,, Llopis S,, González N,, Genovés S,, Mulet AP,, Fernández-Calero T,, Tiscornia I,, Bollati-Fogolín M,, Chambaud I,, Foligné B,, Montserrat A,, Ramón D . 2012. Anti-inflammatory Lactobacillus rhamnosus CNCM I-3690 strain protects against oxidative stress and increases lifespan in Caenorhabditis elegans . PLoS One 7 : e52493.[CrossRef] [PubMed]
24. Laval L,, Martin R,, Natividad JN,, Chain F,, Miquel S,, Desclée de Maredsous C,, Capronnier S,, Sokol H,, Verdu EF,, van Hylckama Vlieg JE,, Bermúdez-Humarán LG,, Smokvina T,, Langella P . 2015. Lactobacillus rhamnosus CNCM I-3690 and the commensal bacterium Faecalibacterium prausnitzii A2-165 exhibit similar protective effects to induced barrier hyper-permeability in mice. Gut Microbes 6 : 1 9.[CrossRef] [PubMed]
25. Bermúdez-Humarán LG . 2009. Lactococcus lactis as a live vector for mucosal delivery of therapeutic proteins. Hum Vaccin 5 : 264 267.[CrossRef] [PubMed]
26. Steidler L,, Hans W,, Schotte L,, Neirynck S,, Obermeier F,, Falk W,, Fiers W,, Remaut E . 2000. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 289 : 1352 1355.[CrossRef] [PubMed]
27. Caluwaerts S,, Vandenbroucke K,, Steidler L,, Neirynck S,, Vanhoenacker P,, Corveleyn S,, Watkins B,, Sonis S,, Coulie B,, Rottiers P . 2010. AG013, a mouth rinse formulation of Lactococcus lactis secreting human trefoil factor 1, provides a safe and efficacious therapeutic tool for treating oral mucositis. Oral Oncol 46 : 564 570.[CrossRef] [PubMed]
28. Kechaou N,, Chain F,, Gratadoux JJ,, Blugeon S,, Bertho N,, Chevalier C,, Le Goffic R,, Courau S,, Molimard P,, Chatel JM,, Langella P,, Bermúdez-Humarán LG . 2013. Identification of one novel candidate probiotic Lactobacillus plantarum strain active against influenza virus infection in mice by a large-scale screening. Appl Environ Microbiol 79 : 1491 1499.[CrossRef] [PubMed]
29. Carroll IM,, Andrus JM,, Bruno-Bárcena JM,, Klaenhammer TR,, Hassan HM,, Threadgill DS . 2007. Anti-inflammatory properties of Lactobacillus gasseri expressing manganese superoxide dismutase using the interleukin 10-deficient mouse model of colitis. Am J Physiol Gastrointest Liver Physiol 293 : G729 G738.[CrossRef] [PubMed]
30. Watterlot L,, Rochat T,, Sokol H,, Cherbuy C,, Bouloufa I,, Lefèvre F,, Gratadoux JJ,, Honvo-Hueto E,, Chilmonczyk S,, Blugeon S,, Corthier G,, Langella P,, Bermúdez-Humarán LG . 2010. Intragastric administration of a superoxide dismutase-producing recombinant Lactobacillus casei BL23 strain attenuates DSS colitis in mice. Int J Food Microbiol 144 : 35 41.[CrossRef] [PubMed]
31. del Carmen S,, de Moreno de LeBlanc A,, Martin R,, Chain F,, Langella P,, Bermúdez-Humarán LG,, LeBlanc JG . 2014. Genetically engineered immunomodulatory Streptococcus thermophilus strains producing antioxidant enzymes exhibit enhanced anti-inflammatory activities. Appl Environ Microbiol 80 : 869 877.[CrossRef] [PubMed]
32. Motta JP,, Magne L,, Descamps D,, Rolland C,, Squarzoni-Dale C,, Rousset P,, Martin L,, Cenac N,, Balloy V,, Huerre M,, Fröhlich LF,, Jenne D,, Wartelle J,, Belaaouaj A,, Mas E,, Vinel JP,, Alric L,, Chignard M,, Vergnolle N,, Sallenave JM . 2011. Modifying the protease, antiprotease pattern by elafin overexpression protects mice from colitis. Gastroenterology 140 : 1272 1282.[CrossRef] [PubMed]
33. Motta JP,, Bermúdez-Humarán LG,, Deraison C,, Martin L,, Rolland C,, Rousset P,, Boue J,, Dietrich G,, Chapman K,, Kharrat P,, Vinel JP,, Alric L,, Mas E,, Sallenave JM,, Langella P,, Vergnolle N . 2012. Food-grade bacteria expressing elafin protect against inflammation and restore colon homeostasis. Sci Transl Med 4 : 158ra144.[CrossRef] [PubMed]
34. Kimura NT,, Taniguchi S,, Aoki K,, Baba T . 1980. Selective localization and growth of Bifidobacterium bifidum in mouse tumors following intravenous administration. Cancer Res 40 : 2061 2068.[PubMed]
35. Yao J,, Wang JY,, Lai MG,, Li YX,, Zhu HM,, Shi RY,, Mo J,, Xun AY,, Jia CH,, Feng JL,, Wang LS,, Zeng WS,, Liu L . 2011. Treatment of mice with dextran sulfate sodium-induced colitis with human interleukin 10 secreted by transformed Bifidobacterium longum . Mol Pharm 8 : 488 497.[CrossRef] [PubMed]
36. Zhang D,, Wei C,, Yao J,, Cai X,, Wang L . 2015. Interleukin-10 gene-carrying bifidobacteria ameliorate murine ulcerative colitis by regulating regulatory T cell/T helper 17 cell pathway. Exp Biol Med (Maywood) 240 : 1622 1629.[CrossRef] [PubMed]
37. Herfarth H,, Schölmerich J . 2002. IL-10 therapy in Crohn’s disease: at the crossroads. Gut 50 : 146 147.[CrossRef] [PubMed]
38. West RL,, Zelinkova Z,, Wolbink GJ,, Kuipers EJ,, Stokkers PC,, van der Woude CJ . 2008. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn’s disease. Aliment Pharmacol Ther 28 : 1122 1126.[CrossRef] [PubMed]
39. Pascual-Salcedo D,, Plasencia C,, Ramiro S,, Nuño L,, Bonilla G,, Nagore D,, Ruiz Del Agua A,, Martínez A,, Aarden L,, Martín-Mola E,, Balsa A . 2011. Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatology (Oxford) 50 : 1445 1452.[CrossRef] [PubMed]
40. Vandenbroucke K,, de Haard H,, Beirnaert E,, Dreier T,, Lauwereys M,, Huyck L,, Van Huysse J,, Demetter P,, Steidler L,, Remaut E,, Cuvelier C,, Rottiers P . 2010. Orally administered L. lactis secreting an anti-TNF nanobody demonstrate efficacy in chronic colitis. Mucosal Immunol 3 : 49 56.[CrossRef] [PubMed]
41. Steidler L,, Neirynck S,, Huyghebaert N,, Snoeck V,, Vermeire A,, Goddeeris B,, Cox E,, Remon JP,, Remaut E . 2003. Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10. Nat Biotechnol 21 : 785 789.[CrossRef] [PubMed]
42. Braat H,, Rottiers P,, Hommes DW,, Huyghebaert N,, Remaut E,, Remon JP,, van Deventer SJ,, Neirynck S,, Peppelenbosch MP,, Steidler L . 2006. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn’s disease. Clin Gastroenterol Hepatol 4 : 754 759.[CrossRef] [PubMed]
43. Limaye SA,, Haddad RI,, Cilli F,, Sonis ST,, Colevas AD,, Brennan MT,, Hu KS,, Murphy BA . 2013. Phase 1b, multicenter, single blinded, placebo-controlled, sequential dose escalation study to assess the safety and tolerability of topically applied AG013 in subjects with locally advanced head and neck cancer receiving induction chemotherapy. Cancer 119 : 4268 4276.[CrossRef] [PubMed]
44. Bermúdez-Humarán LG,, Motta JP,, Aubry C,, Kharrat P,, Rous-Martin L,, Sallenave JM,, Deraison C,, Vergnolle N,, Langella P . 2015. Serine protease inhibitors protect better than IL-10 and TGF-β anti-inflammatory cytokines against mouse colitis when delivered by recombinant lactococci. Microb Cell Fact 14 : 26.[CrossRef] [PubMed]
45. Shaw L,, Wiedow O . 2011. Therapeutic potential of human elafin. Biochem Soc Trans 39 : 1450 1454.[CrossRef] [PubMed]
46. Wei P,, Yang Y,, Ding Q,, Li X,, Sun H,, Liu Z,, Huang J,, Gong Y . 2016. Oral delivery of Bifidobacterium longum expressing α-melanocyte-stimulating hormone to combat ulcerative colitis. J Med Microbiol 65 : 160 168.[CrossRef] [PubMed]

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error